




TORRENT PHARMACEUTICALS LIMITED

Registered Office: Torrent House, Off Ashram Road, Ahmedabad - 380 009, Ph.: +91 79 26599000 Fax: + 91 79 26582100
CIN: L24230GJ1972PLC002126; Website: www.torrentpharma.com; Email: investorservices@torrentpharma.com


[Rs. in Crores except per share data]				
Statement of Standalone Audited Results for the Quarter Ended 30-Jun-2017				
Particulars	Quarter ended			Year ended
	30-Jun-2017	31-Mar-2017	30-Jun-2016	31-Mar-2017
Revenue				
Net Sales (including excise duty)	834	912	1288	4462
Other operating income	13	50	36	131
Revenue from operations (net)	847	962	1324	4593
Other income	109	120	49	299
Total Revenue	956	1082	1373	4892
Expenses				
Cost of materials consumed	239	230	342	1177
Purchases of stock-in-trade	70	60	50	221
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(88)	34	(20)	(11)
Employee benefits expense	187	172	179	699
Finance costs	55	57	48	202
Depreciation and amortisation expense	74	76	61	269
Other expenses	318	356	306	1380
Total expenses	855	985	966	3937
Profit from ordinary activities before tax	101	97	407	955
Tax expense				
Current Tax	22	39	87	222
Deferred Tax	(5)	(56)	(17)	(121)
Total tax expense	17	(17)	70	101
Net profit for the period	84	114	337	854
Other comprehensive income				
Items that will not be reclassified to profit or loss	(3)	(1)	(3)	(11)
Income tax relating to items that will not be reclassified to profit or loss	1	0	1	4
Items that will be reclassified to profit or loss	(67)	85	(5)	158
Income tax relating to items that will be reclassified to profit or loss	23	(29)	2	(55)
Total other comprehensive income	(46)	55	(5)	96
Total comprehensive income	38	169	332	950
Paid-up equity share capital (Face value of Rs. 5 each)	85	85	85	85
Other Equity excluding Revaluation Reserves				4369
Earnings per share (of Rs. 5/- each) (not annualised for the quarter):				
Basic	4.97	6.79	19.95	50.48
Diluted	4.97	6.79	19.95	50.48



Notes:

- 1 The above results were reviewed by the Audit and Risk Management Committee and approved by the Board of Directors in their respective meetings held on 31-July-2017. The auditor have carried out audit of the above said results. There is no qualification in the Auditors report on this statement of financial results.
- 2 The Company operates in a single segment i.e Generic Formulation Business.
- 3 (a) The listed Non Convertible Debentures of the company aggregating to Rs. 990 crores as on 30-Jun-2017 (previous year ended Rs 490 crores) are secured by way of first pari passu charge created through mortgage on certain specified immovable & movable assets and hypothecation of identified trademarks of the Company and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
(b) The listed Non Convertible Debentures of the company aggregating to Rs. 500 crores as on 30-Jun-2017 (previous year ended Rs 1000 crores) to be secured by way of first pari passu charge on certain specified immovable & movable assets and identified trademarks of the Company.
- 4 Results for the year ended 31st March, 2017 and quarter ended 30th June, 2016 include exceptional revenues and profits primarily on account of launch of a new product in the USA which had limited competition.
- 5 The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.

For TORRENT PHARMACEUTICALS LIMITED



SAMIR MEHTA
Executive Chairman

Place : Ahmedabad, Gujarat

Date : 31-July-2017

